Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Tango Therapeutics (TNGX) Other Gross PP&E Adjustments (2020 - 2026)

Tango Therapeutics has reported Other Gross PP&E Adjustments over the past 6 years, most recently at -$18.2 million for Q4 2025.

  • For Q4 2025, Other Gross PP&E Adjustments rose 20.91% year-over-year to -$18.2 million; the TTM value through Dec 2025 reached -$18.2 million, up 20.91%, while the annual FY2025 figure was -$18.2 million, 20.91% up from the prior year.
  • Other Gross PP&E Adjustments for Q4 2025 was -$18.2 million at Tango Therapeutics, up from -$19.2 million in the prior quarter.
  • Over five years, Other Gross PP&E Adjustments peaked at $11.0 million in Q2 2022 and troughed at -$33.3 million in Q3 2022.
  • A 5-year average of -$18.6 million and a median of -$23.6 million in 2024 define the central range for Other Gross PP&E Adjustments.
  • Biggest five-year swings in Other Gross PP&E Adjustments: skyrocketed 404.7% in 2021 and later plummeted 11492.81% in 2022.
  • Year by year, Other Gross PP&E Adjustments stood at $6.1 million in 2021, then plummeted by 629.47% to -$32.3 million in 2022, then rose by 14.61% to -$27.6 million in 2023, then increased by 16.57% to -$23.0 million in 2024, then increased by 20.91% to -$18.2 million in 2025.
  • Business Quant data shows Other Gross PP&E Adjustments for TNGX at -$18.2 million in Q4 2025, -$19.2 million in Q3 2025, and -$20.2 million in Q2 2025.